Highlights include accelerated approval of first MASH therapy; plus Merck’s disease-modifying PAH therapy and Idorsia’s antihypertensive 

Plus: CBC-backed R-Bridge realizes royalty exit, and updates from Akebia, DermBiont, GSK and Flashpoint

CHMP’s June opinions: Amylyx therapy denied, plus positive opinions for two new medicines and eight label extensions

Decisions include GSK’s daprodustat, and two sBLAs for Regeneron’s Eylea

Plus FDA approves Lilly’s Mounjaro, Akebia loses partner, UCB psoriasis candidate hits FDA snag, and updates from Mitsubishi, BridgeBio and more

Plus Karyopharm tumbles, Epizyme cuts, and updates from Alnylam, Novavax, Gilead and more

In deal for Vifor, Australia’s CSL adds registration-stage therapies, established nephrology and iron deficiency products

Plus Junshi-Coherus, FibroGen, EpiEndo, BMS-bluebird, Roche

EU decision could come as early as this month